Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Int J Pharm ; 312(1-2): 196-9, 2006 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-16476530

RESUMEN

In the present study, two indices of acute intestinal permeability changes were investigated as measurements of drug induced intestinal damage. The first method was based on 14C-polyethylene glycol (PEG) 4000 permeability assessment and the second was based on histological evaluation of the intestine. The test compounds were ibuprofen, ketoprofen and naproxen and the alanine, glycine and phenylalanine amide derivatives of ibuprofen. Perfusion studies were carried out using a rat model. Post-perfusion, the gut was fixed and tissue changes were assessed and scored. Ibuprofen, ketoprofen and naproxen altered the barrier properties of the intestine to PEG 4000 with significantly higher scores (p<0.05) for gastrointestinal toxicity relative to blank buffer. For ketoprofen, PEG 4000 permeability and intestinal damage scores increased with increasing ketoprofen concentration. Ibuprofen amide derivatives did not induce significant histological damage or PEG 4000 permeability when compared with ibuprofen. A correlation coefficient of 0.91 is obtained when intestinal damage scores are plotted against PEG 4000 permeability for all compounds. Both indices are proposed as rapid and useful measures of drug induced acute intestinal damage.


Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/farmacocinética , Mucosa Intestinal/metabolismo , Intestinos/patología , Polietilenglicoles/farmacocinética , Alanina/química , Animales , Antiinflamatorios no Esteroideos/química , Glicina/química , Ibuprofeno/efectos adversos , Ibuprofeno/análogos & derivados , Ibuprofeno/química , Ibuprofeno/farmacocinética , Técnicas In Vitro , Cetoprofeno/efectos adversos , Cetoprofeno/farmacocinética , Naproxeno/efectos adversos , Naproxeno/farmacocinética , Permeabilidad , Fenilalanina/química , Ratas
2.
FEMS Microbiol Lett ; 246(2): 199-205, 2005 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-15899406

RESUMEN

Clostridium difficile is a major cause of antibiotic-associated diarrhoea and the primary cause of pseudomembraneous colitis in hospitalised patients. We assessed the protective effect of anti-surface layer protein (SLP) antibodies on C. difficile infection in a lethal hamster challenge model. Post-challenge survival was significantly prolonged in the anti-SLP treated group compared with control groups (P=0.0281 and P=0.0283). The potential mechanism of action of the antiserum was shown to be through enhancement of C. difficile phagocytosis. This report indicates that anti-SLP antibodies can modulate the course of C. difficile infection and may therefore merit closer investigation for use as constituents of multi-component vaccines against C. difficile associated diarrhoea.


Asunto(s)
Anticuerpos Antibacterianos/uso terapéutico , Proteínas Bacterianas/inmunología , Clostridioides difficile/inmunología , Enterocolitis Seudomembranosa/prevención & control , Inmunización Pasiva , Glicoproteínas de Membrana/inmunología , Animales , Anticuerpos Antibacterianos/inmunología , Línea Celular , Cricetinae , Modelos Animales de Enfermedad , Femenino , Humanos , Mesocricetus , Monocitos , Fagocitosis
3.
J Surg Res ; 145(1): 33-40, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17727884

RESUMEN

BACKGROUND: Reflux-induced injury and oxidative stress result in esophageal inflammation and the potential for progression to intestinal metaplasia and adenocarcinoma. Proton-pump inhibitors represent the standard medical approach, but anti-inflammatories and antioxidants offer novel therapeutic possibilities. MATERIALS AND METHODS: Six weeks after an esophagojejunostomy reflux procedure, female Wistar rats (n = 100) were randomized to receive either an antioxidant (vitamin C, 8 mg or 28 mg/day), a cyclooxygenase-2 (COX-2) inhibitor (rofecoxib, 1 mg/day), or no therapy. After sacrifice 16 weeks later, esophageal injury was scored using pathologic and image analysis scoring. RESULTS: Esophagitis was present in all 63 animals completing the study and was severe in 27 (43%). No animal developed metaplasia or tumor. The extent of inflammation and esophageal ulceration were not significantly different between experimental groups. CONCLUSIONS: In this model of reflux injury, antioxidants and COX-2 inhibitors failed to ameliorate the severe inflammation induced. Further experimental designs should evaluate these novel approaches in less severe experimental models.


Asunto(s)
Antioxidantes/uso terapéutico , Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Esofagitis Péptica/prevención & control , Animales , Ácido Ascórbico/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Esofagitis Péptica/etiología , Esofagitis Péptica/patología , Esófago/patología , Esófago/cirugía , Femenino , Yeyuno/cirugía , Lactonas/uso terapéutico , Distribución Aleatoria , Ratas , Ratas Wistar , Sulfonas/uso terapéutico
4.
J Surg Res ; 142(1): 20-7, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17543990

RESUMEN

BACKGROUND: Reflux-induced injury and oxidative stress result in esophageal inflammation and the potential for progression to intestinal metaplasia and adenocarcinoma. Proton-pump inhibitors represent the standard medical approach, but anti-inflammatories and antioxidants offer novel therapeutic possibilities. MATERIALS AND METHODS: Six weeks after an esophagojejunostomy reflux procedure, female Wistar rats (n = 100) were randomized to receive either an antioxidant (vitamin C, 8 mg or 28 mg/day), a cyclooxygenase-2 (COX-2) inhibitor (rofecoxib, 1 mg/day), or no therapy. After sacrifice 16 weeks later, esophageal injury was scored using pathologic and image analysis scoring. RESULTS: Esophagitis was present in all 63 animals completing the study and severe in 27 (43%). No animal developed metaplasia or tumor. The extent of inflammation and esophageal ulceration were not significantly different between experimental groups. CONCLUSIONS: In this model of reflux injury, antioxidants and COX-2 inhibitors failed to ameliorate the severe inflammation induced. Further experimental designs should evaluate these novel approaches in less severe experimental models.


Asunto(s)
Antioxidantes/uso terapéutico , Ácido Ascórbico/uso terapéutico , Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Esofagitis Péptica/prevención & control , Lactonas/uso terapéutico , Sulfonas/uso terapéutico , Animales , Relación Dosis-Respuesta a Droga , Esofagitis Péptica/patología , Esófago/patología , Esófago/cirugía , Femenino , Inflamación/patología , Inflamación/prevención & control , Yeyuno/patología , Yeyuno/cirugía , Modelos Animales , Distribución Aleatoria , Ratas , Ratas Wistar , Úlcera/patología , Úlcera/prevención & control
5.
Mediators Inflamm ; 2005(1): 23-30, 2005 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-15770063

RESUMEN

Studies of tyrosine phosphorylation in the human duodenum have indicated that proliferating cells in the middle portion of the duodenal crypt were devoid of this feature, suggesting that tyrosine kinase activation is not a dominant factor in crypt cell proliferation, and that consequently tyrosine phosphatase activity may be a more critical factor in crypt cell development. We investigated the expression of the leukocyte common antigen-related receptor (LAR) family of tyrosine phosphatases. A flow cytometry system was used to examine cells from the surface, mid-portion, and lower part of the crypt. Individual cell populations were immunostained with anti-LAR antibodies using phycoerythrin-conjugated anti-CD3 to discriminate between epithelial cells (CD3-) and intraepithelial lymphocytes (CD3+). Epithelial cells expressed LAR throughout the crypt. Expression of LAR was maximal in the mid-portion of the crypt with lower expression at the top of the villi. Intraepithelial lymphocytes expressed low levels of LAR at the tips of the villi with stronger expression extending towards the base of the crypt. These findings were confirmed by immunohistochemistry on paraffin-fixed sections. Of note, peripheral blood lymphocytes expressed less LAR than IEL. These observations suggest the possibility that tyrosine phosphatase LAR may be of importance in the regulation of crypt cell proliferation. Moreover, as the extracellular domain of LAR has homology with adhesion molecules, the finding of this molecule on IEL could suggest a possible functional role in homing of this unique lymphocyte.


Asunto(s)
Duodeno/citología , Duodeno/enzimología , Linfocitos/enzimología , Proteínas del Tejido Nervioso/metabolismo , Proteínas Tirosina Fosfatasas/metabolismo , Receptores de Superficie Celular/metabolismo , Complejo CD3/metabolismo , Células Cultivadas , Endotelio Vascular/enzimología , Células Epiteliales/citología , Células Epiteliales/enzimología , Citometría de Flujo/métodos , Humanos , Proteínas del Tejido Nervioso/análisis , Proteínas Tirosina Fosfatasas/análisis , Proteínas Tirosina Fosfatasas Clase 2 Similares a Receptores , Receptores de Superficie Celular/análisis
6.
Hepatology ; 40(1): 108-14, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15239092

RESUMEN

The role of cytotoxic T lymphocyte responses, restricted by human leukocyte antigen (HLA) class I alleles, is recognized as highly significant in the successful clearance of hepatitis C virus (HCV). The frequency of class I alleles in females inoculated with HCV genotype 1b from a single source was examined for an association with outcome. Class I typing was performed using polymerase chain reaction sequence-specific primers in 227 female subjects: 141 had chronic infection and 86 had viral clearance. Statistical analysis included chi(2) testing and multiple logistic regression analysis. A*03, B*27, and Cw*01 occurred more frequently in those with viral clearance (39.5%, 14%, and 9.3%, respectively) compared with those with chronic infection (19.1%, 2.1%, and 1.4%, respectively; P < or = .005). B*08 occurred more often in those with chronic infection compared with viral clearance (39.7% vs. 19.8%; P =.002). In combination with previously reported class II allele associations, over 75% that successfully eliminate HCV carry either A*03, DRB1*0101, or *0401, compared with only 37% of those with chronic infection (P <.0001). The haplotypes A*03-B*07-DRB1*15-DQB1*0602 and A*02-B*27-Cw*01-DRB1*0101-DQB1*0501 are associated with viral clearance (P =.004 and.01, respectively). By multiple logistic regression analysis, the alleles A*03, B*27, DRB1*0101, *0401, and *15 are associated with viral clearance, and B*27 has the strongest association (odds ratio [OR] 7.99). The haplotype A*01-B*08-Cw*07-DRB1*03011-DQB1*0201 is associated with chronic infection (P =.002), being independent for DQB1*0201 (OR 0.27). In conclusion, certain class I alleles are associated with outcome in this homogeneous cohort. More significantly, either HLA-A*03, -DRB1*0101, or -*0401 are carried by an overwhelming majority of those subjects who successfully clear HCV.


Asunto(s)
Alelos , Genes MHC Clase II , Genes MHC Clase I , Hepatitis C Crónica/genética , Hepatitis C Crónica/virología , Carga Viral , Estudios de Cohortes , Contaminación de Medicamentos , Femenino , Antígenos HLA-A/genética , Antígeno HLA-A3 , Antígenos HLA-DR/genética , Cadenas HLA-DRB1 , Hepacivirus , Hepatitis C Crónica/etiología , Humanos , Persona de Mediana Edad , Globulina Inmune rho(D)/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA